Ocucure Therapeutics Inc. (www.OcuCure.com) is an early stage biopharmaceutical company developing new proprietary drugs and technologies to reduce and prevent vision loss caused by eye diseases. The Company's lead product targets wet Age-related Macular Degeneration (AMD), the leading cause of blindness in developed countries. The lead compound has been identified from a portfolio of numerous viable compounds. OcuCure Therapeutics will bring to market a new wave of unique drugs for the treatment of AMD.
Topotarget A/S is a Denmark-based provider of healthcare solutions. The Company's activities cover most aspects of drug development, including assay development, screening, biology, medicinal chemistry, preclinical and clinical trials, regulatory affairs, marketing, licensing and sales. There are two primary areas of development: specialty oncology products, which are marketed by a specialized sales force in Europe, and product candidates with potential broad cancer applications. Some of the Company's partners are CuraGen, active in the research, development and commercialization of HDAC inhibitors in all human diseases; The United States National Cancer Institute, which sponsors clinical trials on PXD101 and also conduct preclinical research on other HDAC inhibitors, and Inhibox, a provider of computational capability in the area of virtual screening for lead identification in its preclinical projects. Topotarget has operations in Denmark, the United Kingdom and Germany.
Lundbeck is an international company with more than 5000 employees. Lundbeck's main office is in Denmark, and the company is represented by subsidiaries and representation offices in 55 countries. More than 60% of our employees are hired outside Denmark, a percentage that has been steadily increasing over the past five years. Lundbeck is a fully integrated pharmaceutical company and thus has competencies in research, development, manufacturing, marketing, sales, and administration. Lundbeck's employees generally possess a high level of education. We are a research enterprise and need specialists with highly specific skills. In most cases this means a university degree. 43.1% of the 1994 employees in Denmark have a university degree. Out of these 12.9% are PhD candidates.
Antisoma plc (Antisoma) is a United Kingdom-based biopharmaceutical company, focused on developing products for the treatment of cancer. The Company has a portfolio of drugs in development, including small molecules, antibody-based therapies and a deoxyribonucleic acid (DNA) aptamer. These drugs act against a range of cancer targets, through different mechanisms, and are being tested in a range of cancer indications that include both solid tumours and blood cancers. The products portfolios of the Company are ASA404, AS1413, Oral fludarabine, AS1411, AS1402, AS1409 and P2045. (Source: ARS)
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. The Company's lead compound under development is Sulonex (sulodexide), formerly KRX-101, an oral heparinoid compound for the treatment of diabetic nephropathy. The Company is developing Zerenex, an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Keryx is also developing clinical-stage oncology compounds, including KRX-0401 (perifosine), an oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. (Source: 10-K)
Elan Corporation, plc (Elan) is a neuroscience-based biotechnology company. Its operations are organized into two business units: Biopharmaceuticals and Elan Drug Technologies (EDT). Biopharmaceuticals engages in research, development and commercial activities primarily areas, such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis (MS), Crohn’s disease (CD) and severe chronic pain. EDT is a specialty pharmaceutical business unit of Elan. Elan’s marketed products in the the United States include PRIALT (ziconotide intrathecal infusion), AZACTAM (aztreonam for injection, USP) and MAXIPIME (cefepime hydrochloride) for Injection. On June 5, 2006, Elan and Biogen Idec announced the approval of a supplemental Biologics License Application (sBLA) by the United States Food and Drug Administration for the reintroduction of TYSABRI (natalizumab) as a monotherapy treatment for relapsing forms of MS to slow the progression of disability and reduce the frequency of clinical relapses.
Angiotech Pharmaceuticals, Inc. is a specialty pharmaceutical and medical device company that discovers, develops and markets technologies primarily focused on acute and surgical applications. The Company generates its revenue through the sales of medical products and components, as well as from royalties derived from sales by its partners of products utilizing certain of its own technologies. The Company operates in two segments: Pharmaceutical Technologies and Medical Products. The Pharmaceuticals Technologies segment includes royalty revenue and gross margin generated from out-licensing technology related to the drug-eluting stent and other technologies. As of December 31, 2007, the Company’s principal revenues in this segment come from royalties derived from sales by Boston Scientific Corporation (BSC) of TAXUS coronary stent systems incorporating the drug paclitaxel. The Medical Products segment includes revenues and gross margins of single use, specialty medical devices. (Source: ARS)
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory